Table 4 Comparison of mean serum 25(OH)D levels at baseline and first follow-up stratified by top 5 cancer sites (N = 799)
From: Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology
Site of tumor | Baseline Mean 25(OH)D in ng/mL (SD) | Follow-up Mean 25(OH)D in ng/mL (SD) | Paired t-test p-value |
|---|---|---|---|
All Cancers (n = 799) | 19.1 (7.5) | 36.2 (17.1) | < 0.001 |
Breast (n = 182) | 19.7 (8.0) | 37.6 (16.8) | < 0.001 |
Lung (n = 120) | 18.4 (7.3) | 41.1 (18.9) | < 0.001 |
Pancreas (n = 60) | 16.2 (7.7) | 30.8 (14.2) | < 0.001 |
Colorectal (n = 90) | 18.7 (7.7) | 31.9 (16.2) | < 0.001 |
Prostate (n = 60) | 20.2 (6.9) | 42.1 (15.9) | < 0.001 |
Others (n = 287) | 19.5 (7.1) | 34.6 (16.8) | < 0.001 |